Evidence map›Paper›PMID 37499237›Full record

ArticleACS applied materials & interfaces2023

Smart Multiplex Point-of-Care Platform for Simultaneous Drug Monitoring.

Duygu Beduk, Tutku Beduk, José Ilton de Oliveira Filho, Abdellatif Ait Lahcen, Ebru Aldemir, Emine Guler Celik, Khaled Nabil Salama, Suna Timur

Open access · hybridAbstract read
In one paragraph

Article in ACS applied materials & interfaces, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
8.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Duygu BedukCentral Research Test and Analysis Laboratory Application and Research Center, Ege University, 35100 Bornova, Izmir, Turkey.ORCID 0000-0002-5394-4967
Tutku BedukSilicon Austria Labs (SAL) GmbH, Europastraße 12, 9500 Villach, Austria.ORCID 0000-0001-7365-6404
José Ilton de Oliveira FilhoSensors Lab, Advanced Membranes and Porous Materials Center, Computer, Electrical, and Mathematical Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.ORCID 0000-0002-8367-4398
Abdellatif Ait LahcenDepartment of Radiology, Weill Cornell Medicine, Dalio Institute for Cardiovascular Imaging, New York, New York 10021, United States.
Ebru AldemirDepartment of Psychiatry, Faculty of Medicine, Izmir Tinaztepe University, 35400 Buca, Izmir, Turkey.
Emine Guler CelikDepartment of Bioengineering, Faculty of Engineering, Ege University, 35100 Bornova, Izmir, Turkey.
Khaled Nabil SalamaSensors Lab, Advanced Membranes and Porous Materials Center, Computer, Electrical, and Mathematical Science and Engineering Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.ORCID 0000-0001-7742-1282
Suna TimurCentral Research Test and Analysis Laboratory Application and Research Center, Ege University, 35100 Bornova, Izmir, Turkey.ORCID 0000-0002-3129-8298
Ege University · TRKing Abdullah University of Science and Technology · SACornell University · USIzmir University · TRSilicon Austria Labs (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recently, illicit drug use has become more widespread and is linked to problems with crime and public health. These drugs disrupt consciousness, affecting perceptions and feelings. Combining stimulants and depressants to suppress the effect of drugs has become the most common reason for drug overdose deaths. On-site platforms for illicit-drug detection have gained an important role in dealing, without any excess equipment, long process, and training, with drug abuse and drug trafficking. Consequently, the development of rapid, sensitive, noninvasive, and reliable multiplex drug-detecting platforms has become a major necessity. In this study, a multiplex laser-scribed graphene (LSG) sensing platform with one counter, one reference, and three working electrodes was developed for rapid and sensitive electrochemical detection of amphetamine (AMP), cocaine (COC), and benzodiazepine (BZD) simultaneously in saliva samples. The multidetection sensing system was combined with a custom-made potentiostat to achieve a complete point-of-care (POC) platform. Smartphone integration was achieved by a customized application to operate, display, and send data. To the best of our knowledge, this is the first multiplex LSG-based electrochemical platform designed for illicit-drug detection with a custom-made potentiostat device to build a complete POC platform. Each working electrode was optimized with standard solutions of AMP, COC, and BZD in the concentration range of 1.0 pg/mL-500 ng/mL. The detection limit of each illicit drug was calculated as 4.3 ng/mL for AMP, 9.7 ng/mL for BZD, and 9.0 ng/mL for COC. Healthy and MET (methamphetamine) patient saliva samples were used for the clinical study. The multiplex LSG sensor was able to detect target analytes in real saliva samples successfully. This multiplex detection device serves the role of a practical and affordable alternative to conventional drug-detection methods by combining multiple drug detections in one portable platform.

Indexed as

Central Nervous System StimulantsCocaineIllicit DrugsMethamphetamineDrug MonitoringHumansPoint-of-Care SystemsCentral Nervous System StimulantsCocaineIllicit DrugsMethamphetamineamphetaminebenzodiazepinecocaineillicit drugslaser-scribed graphenemultiplex sensingpoint-of-care testing (POC)

Identifiers

PMID37499237
PMCPMC10416146
OpenAlexW4385324702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.